DJIA 17,976.31 263.65 1.49%
NASDAQ 4,947.44 0.00 0.00%
S&P 500 2,086.24 25.22 1.22%
market minute promo

Gilead Sciences (NASDAQ: GILD)

100.69 0.00 (0.00%)

REAL-TIME: Last trade at

Extended Hours: $100.08 -$0.61 (-0.61%)
Quote as of (NASDAQ)

company name or ticker

Recent Quotes

GILD $100.69 0.00%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $101.12
Previous Close $100.69
Daily Range $99.57 - $101.66
52-Week Range $63.50 - $116.83
Market Cap $150.0B
P/E Ratio 13.74
Dividend (Yield) $0.00 (0.0%)
Volume 9,962,767
Average Daily Volume 10,052,664
Current FY EPS $9.89




Drug Makers

Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website:

News & Commentary Rss Feed

3 Triple-Digit Stocks With Upside Potential of At Least 40%

Just because these three companies trade north of $100 doesn't mean they're necessarily overvalued. Here are three triple-digit stocks with significant upside potential.

'Fast Money' Recap: A Stock Rally With 'Window Dressing'

Gilead Sciences Inc. Faces An Uncertain Future After Patent Loss In India

The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Achillion Pharmaceuticals

The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Achillion Pharmaceuticals and Cambrex - Press Releases

The Best Dividend-Paying Healthcare Stocks

These three healthcare stocks could offer the best blend of sales and dividend growth in the sector.

3 Best Dividend Stocks for 2015

These stocks offer attractive valuations and promising income streams. Check them out.

Is Gilead Sciences Inc. About to Crater Before Our Very Eyes?

Gilead Sciences has become a battleground stock due to the uncertainty surrounding the future of the hep C market. Here is a look at why the bears might be right in their assessment of this top biotech stock.

The Biggest Red Flag for Biotech Investors

Biotech stocks are chock-full of risk, but some dangers are more significant than others. Here is one key issue biotech investors should be tuned into going forward.

Could These Experimental Drugs Eclipse Harvoni's Historic Launch?

Harvoni set the standard for blockbuster drug launches -- but these three drugs just might have a shot at being even bigger.

Gilead's Hepatitis C Drug Sovaldi Gets Approval in Japan - Analyst Blog

See More GILD News...

GILD's Top Competitors

GILD $100.69 (0.00%)
Current stock: GILD
AMGN $164.31 (1.05%)
Current stock: AMGN
CELG $120.02 (1.13%)
Current stock: CELG
$0.00 (0.00%)
Current stock: